Molecular pathology of thyroid cancer

Diagnostic Histopathology

Volumn 17, Issue 3, 2011, Pages 124-139

  Cassol, Clarissa Araujo ^a   Asa, Sylvia L ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Genetics; Molecular pathology; Pathogenesis; Thyroid cancer

Indexed keywords

ADRENOMEDULLIN; B RAF KINASE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CYCLIN D1; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MELANOMA ANTIGEN 3; MICRORNA; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN RET; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SCATTER FACTOR; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR PAX8; UVOMORULIN;

ANAPLASTIC THYROID CARCINOMA; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER GROWTH; CARCINOGENESIS; CARNEY COMPLEX; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CHROMOSOME 10; CHROMOSOME 10Q; CHROMOSOME 1P; CHROMOSOME REARRANGEMENT; CLINICAL FEATURE; COWDEN SYNDROME; DIMERIZATION; ENZYME ACTIVATION; FAMILIAL NON MEDULLARY THYROID CANCER; GARDNER SYNDROME; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LIGAND BINDING; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CANCER; THYROID CARCINOGENESIS; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; WERNER SYNDROME;

EID: 79952189907     PISSN: 17562317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2010.12.006     Document Type: Article

References (164)

1. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306.
2. Knauf J.A., Fagin J.A. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 2009, 21:296-303.
3. Ciampi R., Nikiforov Y.E. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 2005, 16:163-172.
4. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
5. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signalling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
6. Cohen Y., Xing M., Mambo E., et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95:625-627.
7. Sherman S.I. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 2008, 37:511-524. xi.
8. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404.
9. Chiosea S., Nikiforova M., Zuo H., et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009, 20:122-126.
10. Ciampi R., Knauf J.A., Kerler R., et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005, 115:94-101.
11. Penko K., Livezey J., Fenton C., et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005, 15:320-325.
12. Nikiforova M.N., Ciampi R., Salvatore G., et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 2004, 209:1-6.
13. Ciampi R., Zhu Z., Nikiforov Y.E. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol 2005, 16:99-105.
14. Knauf J.A., Ma X., Smith E.P., et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005, 65:4238-4245.
15. Trovisco V., Vieira D.C.I., Soares P., et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004, 202:247-251.
16. Mitsutake N., Knauf J.A., Mitsutake S., Mesa C., Zhang L., Fagin J.A. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005, 65:2465-2473.
17. Liu D., Liu Z., Condouris S., Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 2007, 92:2264-2271.
18. Handkiewicz-Junak D., Czarniecka A., Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol 2010, 322:8-28.
19. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28:742-762.
20. Takahashi M., Ritz J., Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985, 42:581-588.
21. Arighi E., Borrello M.G., Sariola H. RET tyrosine kinase signalling in development and cancer. Cytokine Growth Factor Rev 2005, 16:441-467.
22. Trupp M., Arenas E., Fainzible M., et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996, 381:785-789.
23. Durbec P., Marcos-Gutierrez C.V., Kilkenny C., et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996, 381:789-793.
24. Mulligan L.M., Ponder B.A.J. Genetic basis of endocrine disease. Multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1995, 80:1989-1995.
25. Mulligan L.M., Kwok J.B.J., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363:458-460.
26. Lairmore T.C., Dou S., Howe J.R., et al. A 1.5-megabase yeast artificial chromosome contig from human chromosome 10q11.2 connecting three genetic loci (RET, D10S94, and D10S102) closely linked to the MEN 2A locus. Proc Natl Acad Sci USA 1993, 90:492-496.
27. Hofstra R.M.W., Landsvater R.M., Ceccherini I., et al. A mutation in the RET proto-oncogene associated with multiple endorineneoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367:375-376.
28. Liu X., Vega Q.C., Decker R.A., Pandey A., Worby C.A., Dixon J.E. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem 1996, 271:5309-5312.
29. Kloos R.T., Eng C., Evans D.B., et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612.
30. Fusco A., Grieco M., Santoro M., et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987, 328:170-172.
31. Santoro M., Melillo R.M., Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 2006, 155:645-653.
32. Adeniran A.J., Zhu Z., Gandhi M., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006, 30:216-222.
33. Nikiforov Y.E., Rowland J.M., Bove K.E., Monforte-Munoz H., Fagin J.A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997, 57:1690-1694.
34. Ito T., Seyama T., Iwamoto K.S., et al. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 1993, 53:2940-2943.
35. Nikiforova M.N., Stringer J.R., Blough R., Medvedovic M., Fagin J.A., Nikiforov Y.E. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 2000, 290:138-141.
36. Gandhi M., Medvedovic M., Stringer J.R., Nikiforov Y.E. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 2006, 25:2360-2366.
37. Sugg S.L., Zheng L., Rosen I.B., Freeman J.L., Ezzat S., Asa S.L. ret/PTC-1,-2 and -3 oncogene rearrangements in human thyroid carcinomas: Implications for metastatic potential?. J Clin Endocrinol Metab 1996, 81:3360-3365.
38. Sugg S.L., Ezzat S., Rosen I.B., Freeman J., Asa S.L. Distinct multiple ret/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 1998, 83:4116-4122.
39. Fusco A., Chiappetta G., Hui P., et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 2002, 160:2157-2167.
40. Fischer A.H., Bond J.A., Taysavang P., Battles O.E., Wynford-Thomas D. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol 1998, 153:1443-1450.
41. Santoro M., Chiappetta G., Cerrato A., et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996, 12:1821-1826.
42. Jhiang S.M., Sagartz J.E., Tong Q., et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996, 137:375-378.
43. Powell D.J., Russell J., Nibu K., et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 1998, 58:5523-5528.
44. Soares P., Fonseca E., Wynford-Thomas D., Sobrinho-Simoes M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?. J Pathol 1998, 185:71-78.
45. Tallini G., Santoro M., Helie M., et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998, 4:287-294.
46. Richardson D.S., Gujral T.S., Peng S., Asa S.L., Mulligan L.M. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. Cancer Res 2009, 69:4861-4869.
47. Martin-Zanca D., Hughes S.H., Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986, 319:743-748.
48. Bongarzone I., Pierotti M.A., Monzini N., et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989, 4:1457-1462.
49. Russell J.P., Powell D.J., Cunnane M., et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 2000, 19:5729-5735.
50. Rabes H.M., Demidchik E.P., Sidorow J.D., et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 2000, 6:1093-1103.
51. Bounacer A., Schlumberger M., Wicker R., et al. Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation. Br J Cancer 2000, 82:308-314.
52. Roccato E., Bressan P., Sabatella G., et al. Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res 2005, 65:2572-2576.
53. Suarez H.G., du Villard J.A., Caillou B., et al. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene 1988, 2:403-406.
54. Lemoine N.R., Mayall E.S., Wyllie F.S., et al. Activated ras oncogenes in human thyroid cancers. Cancer Res 1988, 48:4459-4463.
55. Nikiforova M.N., Nikiforov Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009, 19:1351-1361.
56. Shi Y., Zou M., Schmidt H., et al. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res 1991, 51:2690-2693.
57. Suchy B., Waldmann V., Klugbauer S., Rabes H.M. Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br J Cancer 1998, 77:952-955.
58. Lloyd R.V., Erickson L.A., Casey M.B., et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004, 28:1336-1340.
59. Elsheikh T.M., Asa S.L., Chan J.K., et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 2008, 130:736-744.
60. Garcia-Rostan G., Zhao H., Camp R.L., et al. RAS mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003, 21:3226-3235.
61. Volante M., Rapa I., Gandhi M., et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab 2009, 94:4735-4741.
62. Abulaiti A., Fikaris A.J., Tsygankova O.M., Meinkoth J.L. RAS induces chromosome instability and abrogation of the DNA damage response. Cancer Res 2006, 66:10505-10512.
63. Vitagliano D., Portella G., Troncone G., et al. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 2006, 25:5467-5474.
64. Bondeson L., Bengtsson A., Bondeson A.G., et al. Chromosome studies in thyroid neoplasia. Cancer 1989, 64:680-685.
65. Teyssier J.R., Liautaud-Roger F., Ferre D., Patey M., Dufer J. Chromosomal changes in thyroid tumors. Relation with DNA content, karyotypic features, and clinical data. Cancer Genet Cytogenet 1990, 50:249-263.
66. Sozzi G., Miozzo M., Cariani T.C., et al. A t(2;3)(q12-13;p24-25) in follicular thyroid adenomas. Cancer Genet Cytogenet 1992, 64:38-41.
67. Roque L., Castedo S., Clode A., Soares J. Deletion of 3p25 pter in a primary follicular thyroid carcinoma and its metastasis. Genes Chromosomes Cancer 1993, 8:199-203.
68. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000, 289:1357-1360.
69. Eberhardt N.L., Grebe S.K., McIver B., Reddi H.V. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 2010, 321:50-56.
70. Shen W.T., Chung W.Y. Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. Thyroid 2005, 15:594-599.
71. Lui W.O., Zeng L., Rehrmann V., et al. CREB3L2-PPARgamma fusion mutation identifies a thyroid signalling pathway regulated by intramembrane proteolysis. Cancer Res 2008, 68:7156-7164.
72. Asa S.L. My approach to oncocytic tumours of the thyroid. J Clin Pathol 2004, 57:225-232.
73. Savagner F., Franc B., Guyetant S., Rodien P., Reynier P., Malthiery Y. Defective mitochondrial ATP synthesis in oxyphilic thyroid tumors. J Clin Endocrinol Metab 2001, 86:4920-4925.
74. Maximo V., Soares P., Lima J., Cameselle-Teijeiro J., Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002, 160:1857-1865.
75. Bonora E., Porcelli A.M., Gasparre G., et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006, 66:6087-6096.
76. Gasparre G., Porcelli A.M., Bonora E., et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A 2007, 104:9001-9006.
77. Gasparre G., Bonora E., Tallini G., Romeo G. Molecular features of thyroid oncocytic tumors. Mol Cell Endocrinol 2010, 321:67-76.
78. Cheung C.C., Ezzat S., Ramyar L., Freeman J.L., Asa S.L. Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 2000, 85:878-882.
79. Chiappetta G., Toti P., Cetta F., et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 2002, 87:364-369.
80. Weber F., Aldred M.A., Morrison C.D., et al. Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J Clin Endocrinol Metab 2005, 90:1149-1155.
81. Katoh R., Harach H.R., Williams E.D. Solitary, multiple, and familial oxyphil tumours of the thyroid gland. J Pathol 1998, 186:292-299.
82. Canzian F., Amati P., Harach H.R., et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998, 63:1743-1748.
83. Maximo V., Botelho T., Capela J., et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 2005, 92:1892-1898.
84. Bonora E., Evangelisti C., Bonichon F., Tallini G., Romeo G. Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br J Cancer 2006, 95:1529-1536.
85. Bonora E., Tallini G., Romeo G. Genetic predisposition to familial nonmedullary thyroid cancer: an update of molecular findings and state-of-the-art studies. J Oncol 2010, 2010:385206.
86. Bignell G.R., Canzian F., Shayeghi M., et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997, 61:1123-1130.
87. Malchoff C.D., Sarfarazi M., Tendler B., et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000, 85:1758-1764.
88. McKay J.D., Lesueur F., Jonard L., et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001, 69:440-446.
89. Cavaco B.M., Batista P.F., Sobrinho L.G., Leite V. Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. J Clin Endocrinol Metab 2008, 93:4426-4430.
90. Khan A., Smellie J., Nutting C., Harrington K., Newbold K. Familial nonmedullary thyroid cancer: a review of the genetics. Thyroid 2010, 20:795-801.
91. Kondo T., Zheng L., Liu W., Kurebayashi J., Asa S.L., Ezzat S. Epigenetically controlled fibroblast growth factor receptor 2 signalling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 2007, 67:5461-5470.
92. Kondo T., Zhu X., Asa S.L., Ezzat S. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res 2007, 13:4713-4720.
93. St Bernard R., Zheng L., Liu W., Winer D., Asa S.L., Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005, 146:1145-1153.
94. Elliott D.D., Sherman S.I., Busaidy N.L., et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 2008, 39:15-20.
95. Masago K., Asato R., Fujita S., et al. Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer 2009, 124:2744-2749.
96. Lee D.H., Lee G.K., Kong S.Y., et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 2007, 60:881-884.
97. Jo Y.S., Li S., Song J.H., et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006, 91:3667-3670.
98. Khoo M.L., Ezzat S., Freeman J.L., Asa S.L. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 2002, 87:1810-1813.
99. Khoo M.L., Beasley N.J., Ezzat S., Freeman J.L., Asa S.L. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002, 87:1814-1818.
100. Liu W., Asa S.L., Fantus I.G., Walfish P.G., Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/Akt-dependent and -independent pathways. Am J Pathol 2002, 160:511-519.
101. Dackiw A.P., Ezzat S., Huang P., Liu W., Asa S.L. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004, 145:5840-5846.
102. Nakamura T., Yana I., Kobayashi T., et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992, 83:1293-1298.
103. Caballero O.L., Chen Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021.
104. Liu W., Cheng S., Asa S.L., Ezzat S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008, 68:8104-8112.
105. Cheng S., Liu W., Mercado M., Ezzat S., Asa S.L. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. Endocr Relat Cancer 2009, 16:455-466.
106. Garcia-Rostan G., Camp R.L., Herrero A., Carcangiu M.L., Rimm D.L., Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001, 158:987-996.
107. von Wasielewski R., Rhein A., Werner M., et al. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997, 57:2501-2507.
108. Kato N., Tsuchiya T., Tamura G., Motoyama T. E-cadherin expression in follicular carcinoma of the thyroid. Pathol Int 2002, 52:13-18.
109. Rocha A.S., Soares P., Fonseca E., Cameselle-Teijeiro J., Oliveira M.C., Sobrinho-Simoes M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 2003, 42:580-587.
110. Castellone M.D., De F.V., Rao D.M., et al. The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 2009, 69:1867-1876.
111. Gujral T.S., van Veelen W., Richardson D.S., et al. A novel RET kinase-beta-catenin signalling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res 2008, 68:1338-1346.
112. Oler G., Camacho C.P., Hojaij F.C., Michaluart P., Riggins G.J., Cerutti J.M. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 2008, 14:4735-4742.
113. Guarino V., Faviana P., Salvatore G., et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 2005, 90:5270-5278.
114. Briese J., Ezzat S., Liu W., et al. Osteopontin expression in thyroid carcinoma. Anticancer Res 2010, 30:111-122.
115. Liu W., Wei W., Winer D., et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 2007, 26:2747-2758.
116. Huang Y., Prasad M., Lemon W.J., et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001, 98:15044-15049.
117. Aldred M.A., Huang Y., Liyanarachchi S., et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 2004, 22:3531-3539.
118. Prasad M.L., Pellegata N.S., Kloos R.T., Barbacioru C., Huang Y., de la Chapelle A. CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 2004, 14:169-175.
119. Ryu S., Jimi S., Eura Y., Kato T., Takebayashi S. Strong intracellular and negative peripheral expression of fibronectin in tumor cells contribute to invasion and metastasis in papillary thyroid carcinoma. Cancer Lett 1999, 146:103-109.
120. Liu W., Asa S.L., Ezzat S. 1{alpha},25-dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. Mol Endocrinol 2005, 19:2349-2357.
121. Takano T., Matsuzuka F., Miyauchi A., et al. Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study. Br J Cancer 1998, 78:221-224.
122. Wehmeier M., Petrich T., Brand K., Lichtinghagen R., Hesse E. Oncofetal fibronectin mRNA is highly abundant in the blood of patients with papillary thyroid carcinoma and correlates with high-serum thyroid-stimulating hormone levels. Thyroid 2010, 20:607-613.
123. Garcia-Rostan G., Costa A.M., Pereira-Castro I., et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005, 65:10199-10207.
124. Hou P., Liu D., Shan Y., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007, 13:1161-1170.
125. Wang Y., Hou P., Yu H., et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 2007, 92:2387-2390.
126. Santarpia L., El Naggar A.K., Cote G.J., Myers J.N., Sherman S.I. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008, 93:278-284.
127. Ricarte-Filho J.C., Ryder M., Chitale D.A., et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009, 69:4885-4893.
128. Saji M., Ringel M.D. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 2010, 321:20-28.
129. Takano T., Hasegawa Y., Matsuzuka F., et al. Gene expression profiles in thyroid carcinomas. Br J Cancer 2000, 83:1495-1502.
130. Barden C.B., Shister K.W., Zhu B., et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 2003, 9:1792-1800.
131. Wasenius V.M., Hemmer S., Kettunen E., Knuutila S., Franssila K., Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 2003, 9:68-75.
132. Yano Y., Uematsu N., Yashiro T., et al. Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 2004, 10:2035-2043.
133. Hawthorn L., Stein L., Varma R., Wiseman S., Loree T., Tan D. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck 2004, 26:1069-1083.
134. Taniguchi K., Takano T., Miyauchi A., et al. Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction. Oncology 2005, 69:428-435.
135. Finley D.J., Arora N., Zhu B., Gallagher L., Fahey T.J. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004, 89:3214-3223.
136. Chevillard S., Ugolin N., Vielh P., et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 2004, 10:6586-6597.
137. Onda M., Emi M., Yoshida A., et al. Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocr Relat Cancer 2004, 11:843-854.
138. Cerutti J.M., Delcelo R., Amadei M.J., et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 2004, 113:1234-1242.
139. Wreesmann V.B., Sieczka E.M., Socci N.D., et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 2004, 64:3780-3789.
140. Weber F., Shen L., Aldred M.A., et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 2005, 90:2512-2521.
141. Fryknas M., Wickenberg-Bolin U., Goransson H., et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 2006, 27:211-220.
142. Zhao J., Leonard C., Brunner E., Gemsenjager E., Heitz P.U., Odermatt B. Molecular characterization of well-differentiated human thyroid carcinomas by cDNA arrays. Int J Oncol 2006, 29:1041-1051.
143. Fujarewicz K., Jarzab M., Eszlinger M., et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer 2007, 14:809-826.
144. Murphy K.M., Chen F., Clark D.P. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling. Hum Pathol 2008, 39:420-426.
145. Montero-Conde C., Martin-Campos J.M., Lerma E., et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 2008, 27:1554-1561.
146. Zhao J., Leonard C., Gemsenjager E., Heitz P.U., Moch H., Odermatt B. Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling. Oncol Rep 2008, 19:329-337.
147. Pita J.M., Banito A., Cavaco B.M., Leite V. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer 2009, 101:1782-1791.
148. Fontaine J.F., Mirebeau-Prunier D., Raharijaona M., et al. Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers. PLoS ONE 2009, 4:e7632.
149. Nikiforova M.N., Chiosea S.I., Nikiforov Y.E. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 2009, 20:85-91.
150. He H., Jazdzewski K., Li W., et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005, 102:19075-19080.
151. Pallante P., Visone R., Ferracin M., et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006, 13:497-508.
152. Felli N., Fontana L., Pelosi E., et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005, 102:18081-18086.
153. Weber F., Teresi R.E., Broelsch C.E., Frilling A., Eng C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:3584-3591.
154. Visone R., Russo L., Pallante P., et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007, 14:791-798.
155. Tetzlaff M.T., Liu A., Xu X., et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007, 18:163-173.
156. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008, 93:1600-1608.
157. Visone R., Pallante P., Vecchione A., et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007, 26:7590-7595.
158. Takakura S., Mitsutake N., Nakashima M., et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 2008, 99:1147-1154.
159. Kim H.J., Kim Y.H., Lee D.S., Chung J.K., Kim S. In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma. J Nucl Med 2008, 49:1686-1693.
160. Mitomo S., Maesawa C., Ogasawara S., et al. Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 2008, 99:280-286.
161. Gudmundsson J., Sulem P., Gudbjartsson D.F., et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 2009, 41:460-464.
162. Kouniavsky G., Zeiger M.A. Thyroid tumorigenesis and molecular markers in thyroid cancer. Curr Opin Oncol 2010, 22:23-29.
163. Jazdzewski K., Murray E.L., Franssila K., Jarzab B., Schoenberg D.R., de la C.A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008, 105:7269-7274.
164. Sheu S.Y., Handke S., Brocker-Preuss M., et al. The C allele of the GNB3 C825T polymorphism of the G protein beta3-subunit is associated with an increased risk for the development of oncocytic thyroid tumours. J Pathol 2007, 211:60-66.